Graybug Vision (GRAY) Stock Price, News & Analysis

Company Overview

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD). The company is also advancing GB-401, a sustained-release formulation of travoprost for the management of open-angle glaucoma.

Graybug Vision’s clinical development program for GB-102 has included Phase I/II studies in patients with wet AMD, demonstrating a favorable safety profile and potential for extended dosing intervals compared to existing standards of care. The company has expanded its clinical footprint into multiple centers across the United States and has established collaborations with ophthalmology specialists to support ongoing and future trials. In parallel, preclinical and early clinical work on GB-401 aims to address unmet needs in glaucoma management by offering sustained intraocular pressure control without the need for daily eye drops.

Founded with the mission of transforming ophthalmology through sustained-delivery technologies, Graybug Vision is headquartered in New York City. The company is led by President and Chief Executive Officer David R. Guyer, M.D., who brings over two decades of experience in ophthalmic drug development. Under his leadership, Graybug has assembled a team with deep expertise in pharmacology, formulation science, and clinical trial execution, positioning the company to advance its pipeline and explore additional indications for its Depot Technology Platform.

Key Stats

• Today's Range: $2.87 to $3.12
• 50-Day Range: $1.59 to $3.80
• 52-Week Range: $5.00 to $22.12
• Volume: 39,041 shs
• Average Volume: 2,165 shs
• Market Capitalization: $4.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GRAY Stock Analysis - Frequently Asked Questions

How have GRAY shares performed this year?

Graybug Vision's stock was trading at $3.29 at the start of the year. Since then, GRAY shares have decreased by 13.4% and is now trading at $2.85.

How were Graybug Vision's earnings last quarter?

Graybug Vision, Inc. (NASDAQ:GRAY) issued its quarterly earnings data on Thursday, November, 11th. The company reported ($5.32) earnings per share for the quarter, missing analysts' consensus estimates of ($5.18) by $0.14.

When did Graybug Vision's stock split?

Shares of Graybug Vision reverse split on Monday, March 20th 2023.The 1-14 reverse split was announced on Monday, March 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Graybug Vision IPO?

Graybug Vision (GRAY) raised $75 million in an IPO on Friday, September 25th 2020. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. SVB Leerink and Piper Sandler served as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers.

How do I buy shares of Graybug Vision?

Shares of GRAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Graybug Vision own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Graybug Vision investors own include Tesla (TSLA), Plug Power (PLUG), Athenex (ATNX), NIO (NIO), Moderna (MRNA), Pinterest (PINS).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GRAY
• CIK: 1534133
• Web: www.graybug.com
• Phone: N/A
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($24.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.61%
• Return on Assets: -71.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.73
• Quick Ratio: 10.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 1,571,000
• Free Float: 20,250,000
• Market Cap: $4.48 million
• Optionable: Not Optionable
• Beta: 1.20